SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study

Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis

(2021) Yi-Wen Yu et al.   Cardiovascular Diabetology

Low-blood pressure phenotype underpins the tendency to reflex syncope

(2021) Michele Brignole et al.   JOURNAL OF HYPERTENSION

Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators

(2021) Pasquale Paolisso et al.   DIABETES CARE

Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction

(2021) Celestino Sardu et al.   Biomedicines

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up

(2021) Celestino Sardu et al.   Frontiers in Pharmacology

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice

(2020) Thiquynhnga Nguyen et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

(2019) Akira Sezai et al.   Cardiovascular Diabetology

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

(2019) Kenneth W. Mahaffey et al.   CIRCULATION

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

(2019) Jesper Jensen et al.   Trials

Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure

(2019) André J. Scheen   Current Cardiology Reports

A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity

(2018) Motoaki Sano   Journal of Cardiology

ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause

(2018) Celestino Sardu et al.   MEDICINE

Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats

(2017) Tomoko Yoshikawa et al.   HYPERTENSION RESEARCH

Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2

(2017) Vance B. Matthews et al.   JOURNAL OF HYPERTENSION

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus

(2017) Jens Jordan et al.   Journal of the American Society of Hypertension

Mechanisms of Vasovagal Syncope in the Young: Reduced Systemic Vascular Resistance Versus Reduced Cardiac Output

(2017) Julian M. Stewart et al.   Journal of the American Heart Association

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Spontaneous vs nitroglycerin-induced vasovagal reflex on head-up tilt: Are there neuroendocrine differences?

(2016) David Nilsson et al.   HEART RHYTHM

A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

(2016) Yui Takeshige et al.   HYPERTENSION RESEARCH

Is it time to think about the sodium glucose co-transporter 2 sympathetically?

(2016) Rosemary H Elliott et al.   NEPHROLOGY

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

(2015) Sunder Mudaliar et al.   DIABETES CARE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Novel cardiovascular biomarkers in unexplained syncopal attacks: the SYSTEMA cohort

(2013) A. Fedorowski et al.   JOURNAL OF INTERNAL MEDICINE

Predictors of Mortality, Rehospitalization for Syncope, and Cardiac Syncope in 352 Consecutive Elderly Patients With Syncope

(2013) Sahil Khera et al.   Journal of the American Medical Directors Association

Cardiac autonomic disturbances in patients with vasovagal syndrome: comparison between iodine-123-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability

(2012) G. Kochiadakis et al.   EUROPACE